In summary, the safety, efficacy and compliance of GB05 have been significantly improved. Currently, phase III clinical trials for GB05 are on going in China. Kexing Biopharm has been deeply engaged ...

CHATHAM, N.J. - Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), a biopharmaceutical company with a market capitalization ...

Conferences on Antiviral Research present a wealth of new information on novel drug development and the 21st annual meeting, held in Montreal between 13-17 April 2008, was no exception.

The constant need to refill the antiviral drug pipeline to keep up with the emergence ... Antiviral drug development is thus focusing not only on viral targets (e.g., HIV reverse transcriptase ...

In a challenging market environment, Hemispherx Biopharma Inc (NYSE:AIM), trading under the ticker AIM, has seen its stock price touch a 52-week low, reaching a sobering $0.13, marking an 82% decline ...

Approximately 9.5% (US$15.7 million) of global funding was focused on drug development ... the only factor contributing to the absence of antiviral drugs against dengue, but there can be no ...

NanoViricides, Inc. (NYSE American:NNVC) (the 'Company') declared today that it is ready to fight the bird flu with its revolutionary ...

Therefore development of NV-387, a broad-spectrum host-mimetic, direct-acting antiviral drug that the viruses cannot escape even as they change constantly, will be revolutionary once the drug ...

AIM ImmunoTech (AIM) announced its initiation of a plan to advance Ampligen as a vaccine adjuvant for avian influenza as part of the Company’s ...

NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that it has engaged a Clinical Research Organization (CRO) to conduct a Phase II clinical trial advancing its broad-spectrum ...